verteporfin + Detox-B

**Verteporfin + Detox-B** is a combination therapy used in photodynamic therapy (PDT), particularly for oncology indications such as advanced cancer and experimental treatment of breast cancer. Verteporfin is a small molecule photosensitizer, typically administered in liposomal formulation, that upon activation by light generates reactive oxygen species leading to targeted cytotoxicity and disruption of tumor vasculature. Detox-B (also identified as 5-azadeoxycytidine or 5-ADC in some studies) is an immunomodulatory and epigenetic agent that inhibits DNA methylation through suppression of DNA methyltransferase 1 (Dnmt1), restoring tumor suppressor gene expression and boosting antitumor immunity. The combination acts synergistically by enhancing apoptosis, modulating tumor immunity, and promoting cytotoxicity against tumor cells, with Verteporfin providing the photochemical effect and Detox-B amplifying the antitumor response through epigenetic modulation and immune activation. This regimen has been investigated in clinical trials for advanced solid malignancies and preclinical models for triple-negative breast cancer[1][2].